Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Abstract

Objective: To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine.

Methods: A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migraine (Evaluation of Galcanezumab in the Prevention of Chronic Migraine [REGAIN]) was a phase 3 study with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Eligible patients 18 to 65 years of age with chronic migraine were randomized 2:1:1 to monthly subcutaneous injections of placebo (n = 558), galcanezumab 120 mg (with a 240-mg loading dose, n = 278), or galcanezumab 240 mg (n = 277). The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days (MHDs) during the 3-month double-blind treatment phase.

Results: Mean number of monthly MHDs at baseline was 19.4 for the total sample. Both galcanezumab dose groups demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo (placebo -2.7, galcanezumab 120 mg -4.8, galcanezumab 240 mg -4.6) (p < 0.001 for each dose compared to placebo). There were no clinically meaningful differences between galcanezumab doses and placebo on any safety or tolerability outcome except for a higher incidence of treatment-emergent injection-site reaction (p < 0.01), injection-site erythema (p < 0.001), injection-site pruritus (p < 0.01), and sinusitis (p < 0.05) in the galcanezumab 240-mg group relative to placebo.

Conclusions: Both doses of galcanezumab were superior to placebo in reducing the number of monthly MHDs. Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.

Clinicaltrialsgov identifier: NCT02614261.

Classification of evidence: This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Multiple testing procedure

Arrows indicate direction and weighting of α propagation. The procedure initially tests the parallel branches (dose sequences) simultaneously and then recycles available α between the branches to retest endpoint families containing nonrejected null hypotheses. Notation is consistent with previously reported methods. Acute meds = MHD with the use of acute (abortive) treatment; MHD = migraine headache days (mean change from baseline); MSQ = Migraine-Specific Quality of Life Questionnaire Role Function-Restrictive domain; PGI-S = Patient Global Impression of Severity; RR = response rate.

Figure 2. Patient cohort diagram of the double-blind phase of the REGAIN study

REGAIN = Evaluation of Galcanezumab in the Prevention of Chronic Migraine.

Figure 3. Reduction in MHDs at each month

Reduction in migraine headache days (MHDs) at each month was statistically greater in both galcanezumab dose groups compared with placebo. Differences between galcanezumab doses were not significant. LS = least squares; SE = standard error. ***p < 0.001 vs placebo; **p < 0.01 vs placebo.

Figure 4. Mean percentages of patients with ≥50%, ≥75%, or 100% response across months 1 through 3

Response refers to percent reduction from baseline in monthly migraine headache days. Differences between galcanezumab doses were not significant. SE = standard error. ***p < 0.001 (statistically significant vs placebo after multiplicity adjustment); *p < 0.05 (not statistically significant after multiplicity adjustment).